1. Anticancer Agents Based on Vulnerable Components in a Signalling Pathway
    Ankur Vaidya et al, 2020, Mini-Reviews in Medicinal Chemistry CrossRef
  2. DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome
    Kristyna Tomasova et al, 2020, Cancers CrossRef
  3. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
    Jennifer H. Foster et al, 2021, International Journal of Molecular Sciences CrossRef
  4. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
    Ainhoa Madariaga et al, 2019, Cancers CrossRef
  5. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma
    Zejia Yang et al, 2022, Cancer Chemotherapy and Pharmacology CrossRef
  6. WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage
    Mathilde Rikje Willemijn de Jong et al, 2019, Cancers CrossRef
  7. Structure-activity relationships of Wee1 inhibitors: A review
    Xingkai Du et al, 2020, European Journal of Medicinal Chemistry CrossRef
  8. ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models
    Jie Li et al, 2023, Journal of Clinical Investigation CrossRef

  9. Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets


    Ioannis A Voutsadakis, 2020, Cancer Management and Research CrossRef
  10. Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy
    Francesca Esposito et al, 2021, International Journal of Molecular Sciences CrossRef
  11. Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit
    Genevieve V. Dall et al, 2022, Cancers CrossRef
  12. HREM, RNAseq and Cell Cycle Analyses Reveal the Role of the G2/M-Regulatory Protein, WEE1, on the Survivability of Chicken Embryos during Diapause
    Narayan Pokhrel et al, 2022, Biomedicines CrossRef
  13. Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process
    Yu-Li Su et al, 2023, Cells CrossRef
  14. Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma
    Drumond-Bock Ana Luiza et al, 2023, Genes & Cancer CrossRef
  15. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
    Naoko Takebe et al, 2021, Clinical Cancer Research CrossRef
  16. DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities
    María Ovejero-Sánchez et al, 2023, Cancers CrossRef
  17. The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma
    Long Liang et al, 2020, British Journal of Haematology CrossRef
  18. WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma
    Rovingaile Kriska M. Ponce et al, 2022, JCI Insight CrossRef
  19. Development and Characterization of a Wee1 Kinase Degrader
    Zhengnian Li et al, 2020, Cell Chemical Biology CrossRef
  20. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy
    Siqing Fu et al, 2018, Expert Opinion on Investigational Drugs CrossRef
  21. SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis
    Anthony Williams et al, 2023, Cancer Letters CrossRef
  22. Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155–5p to regulate WEE1 expression
    Yang Yang et al, 2021, Pathology - Research and Practice CrossRef
  23. Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation
    Harvey E. Johnston et al, 2018, Molecular & Cellular Proteomics CrossRef
  24. Discovery of potential WEE1 inhibitors via hybrid virtual screening
    Tingting Jin et al, 2023, Frontiers in Pharmacology CrossRef
  25. Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
    Alexandra N. Corella et al, 2020, Clinical Cancer Research CrossRef
  26. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines
    Rebecca S.S. Barbosa et al, 2019, Biochemical and Biophysical Research Communications CrossRef